Tyme Technologies Inc (NASDAQ:TYME)
| 0.309 BATS BZX Real-Time Price As of 12:47pm ET |  +0.0425 / +15.95%Today’s Change | 0.22 Today|||52-Week Range 2.02 | -48.76% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $45.3M |
Company Description
Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ.
Contact Information
Tyme Technologies, Inc. 1 Pluckemin Way Bedminster New Jersey 07921 |
Employees
Shareholders
| Other institutional | 5.55% |
| Individual stakeholders | 31.13% |
| Mutual fund holders | 3.02% |
Top Executives
| Richard Anthony Cunningham | Chief Executive Officer & Director |
| Frank L. Porfido | Chief Financial Officer |
| Jan M. van Tornout | Chief Medical Officer |
| Jonathan M. Eckard | Chief Business Officer |
| John M. Rothman | Executive Vice President-Product Development |
